Abstract:OBJECTIVE:Acute monocytic leukemia (AML)-M5 is the common type of acute myeloid leukemias in children. Studies have shown that there are abundant lipopolysaccharide (LPS) receptor (designated as CD14) molecules on the cell membrane of M5 cells and they play an important role in the diagnosis of M5, since they can be recognized and bound by mouse-anti-human CD14 monoclonal antibody (McAb). However, mouse-originated antibodies are largely not suitable for clinical application due to the severe side effects, thus "humanized antibody" is desired. As the first step for developing humanized antibody, the construction and expression of single chain antibody (scFv) with functional protein are necessary. The present study aimed to express ZCH-7-2F9 ScFv (scFv(2F9)) in eukaryotic cells and obtain the scFv(2F9) protein with a high biological activity.METHODS:Four primers were synthesized to construct the eukaryotic expressional vector, which included SfiI and EcoRI enzyme cleaving site, 6 x His and stop code TGA sequences. scFv(2F9) gene was amplified through splicing by overlap extension (SOE) using the high fidelity Taq polymerase. Positive recombinants (pSectag2A/scFv(2F9)) were identified through enzyme cleaving and sequenced before expression and were transformed into Chinese hamster ovary (CHO) cells for expression. Western-Blot and flow cytometry (FCM) were carried out to determine the relative molecular mass (Mr) and binding activity of scFv(2F9).RESULTS:The cloned scFv(2F9) gene was identified to be functional by sequencing and expressing. The interested protein could be detected in the culture supernatant of transformed CHO cells with an Mr of 31 000. The blocking test showed that the positive cell percentages, the mean fluorescence intensity (MFI) and the peak of channel (peak Ch) were reduced by 90.02%, 63.30% and 63.38%, respectively after blocking with scFv(2F9), while those were 4.55%, 10.09% and 5.02% after blockage using the supernatant from the CHO cells transfected with blanked vector pSectag2A.CONCLUSIONS:The scFv(2F9) against human CD14 antigen was successfully expressed in eukaryotic cells and showed a high biological activity, which may be useful for the further studies on its humanized antibodies.

Expression of Single Chain Variable Fragment A7 Gene in Myasthenia Gravis in Pichia Pastoris

Characterization of Expressed Anti-Cetylcholine Receptor Single Chain Variable Fragment in Pichia Pastoris

Construction of Eukaryotic Expression Vector of Gene of Single Chain Variable Fragment A7

Construction of Gene of Single Chain Variable Fragment Against Acetylcholine Receptor in Myasthenia Gravis

Expression of Ascaris suum cecropin P1 gene in Pichia pastoris and its antimicrobial activity

Fusion Protein of Single-Chain Variable Domain Fragments for Treatment of Myasthenia Gravis

The cloning and expression of single-chain Fv antibody gene fragments against acetylcholine receptor

Construction and Expression of a Fusion Protein of Scfv Against Human Acetylcholine Receptor-Human Serum Albumin in E.coli

Construction of Eukaryotic Expression Vector of AChR-IgG Fc Fragment Fusion Protein and Its Expression in CHOk1 Cells

Construction of Prokaryotic Vector and Bacteria Expressing Single-chain Fv Antibody Fragments Against Acetylcholine Receptor

Preparation of Single Chain Variable Fragment Gene in Myasthenia Gravis

Potential Roles of Recombinant Acetylcholine Receptor Α Subunit 1–211 in Immunoadsorbent and DNA Immunization

Artificial Construction of Human Pathogenic Autoantibody in Myasthenia Gravis

Expression of a highly antigenic and native-like folded extracellular domain of the human α1 subunit of muscle nicotinic acetylcholine receptor, suitable for use in antigen specific therapies for Myasthenia Gravis

Construction and Expression of a Fusion Protein Containing Extracellular Domain of Human AChRα1 and Fc Fragment of Human IgG1

[Eukaryotic Expression and Determination of ZCH-7-2F9 Single Chain Antibody Against Human CD14].

Pathogenicity and sequence analysis of a mouse anti-AChR monoclonal antibody A7

Construction of a myasthenia gravis model by immunizing mice with gene vaccine pcDNA-AChR_(α211)

[Expression and identification of recombinant mouse gene B7-H4].

Inhibition of Sera from Patients with Myasthenia Gravis to the Binding of Acetylcholine Receptor by a Fusion Protein of Antibody Fragment and Albumin

Construction of Eukaryotic Expression Vector of a Fusion Gene of Single Chain Variable Fragment Directed Against Acetylcholine Receptor with Human Serum Albumin